TFA Therapeutics (RAJAF) Operating Leases (2020 - 2024)

TFA Therapeutics has reported Operating Leases for 5 years, with the latest figure at $12602.0 in Q4 2024.

• On a quarterly basis, Operating Leases fell 88.15% year-over-year to $12602.0 in Q4 2024; TTM through Dec 2024 was $12602.0, a 88.15% decrease from a year earlier, with the FY2024 full-year figure at $12602.0, down 88.15% from the prior year.
• Operating Leases was $12602.0 for Q4 2024 at TFA Therapeutics, down from $106356.0 in the prior quarter.
• The five-year high for Operating Leases was $203325.0 in Q4 2021, with the low at $11056.0 in Q4 2020.
• Average Operating Leases over 5 years is $92620.8, with a median of $103842.5 recorded in 2023.
• The sharpest annual moves came in 2021 and 2024: Operating Leases surged 1739.05% in 2021, then plunged 88.15% in 2024.
• Over 5 years, Operating Leases stood at $11056.0 in 2020, then soared by 1739.05% to $203325.0 in 2021, then plunged by 40.46% to $121057.0 in 2022, then fell by 12.14% to $106356.0 in 2023, then slumped by 88.15% to $12602.0 in 2024.
• The last three Operating Leases figures came in at $12602.0 (Q4 2024), $106356.0 (Q4 2023), and $101329.0 (Q3 2023), per Business Quant data.